PURPOSE: Idiopathic Pulmonary Fibrosis (IPF) is characterized by progressive respiratory
insufficiency and a median survival of only 2-5 years. There is no therapy for IPF with …

Objective: To examine the clinical aspects of idiopathic pulmonary fibrosis (IPF) and the
efficacy and safety of interferon gamma-1b (IFNγ− 1b) in its treatment. Data Sources …

Background Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known
efficacious therapy. Methods In a double-blind, multinational trial, we randomly assigned …

Idiopathic pulmonary fibrosis (IPF) is a disease with progressive and devastating
deterioration of lung function and a fatal prognosis, despite aggressive therapeutic attempts …

Background: The only proven therapeutic option for idiopathic pulmonary fibrosis (IPF) is
lung transplantation. It is biologically plausible that interferon gamma-1b (G-IFN) may halt or …

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease that prognosis (INF) has
not improved by available therapy. Recently, much attention has focused on the utility of the …

Context Despite the investigation of multiple therapeutic options, idiopathic pulmonary
fibrosis (IPF) remains a devastating, progressively fatal disease. Much interest has focused …

OBJECTIVE To report on observations made in a group of patients with idiopathic
pulmonary fibrosis/usual interstitial pneumonia (IPF/UIP) who were treated with interferon …

Background Idiopathic pulmonary fibrosis (IPF) is a devastating disease, yet validated,
reliable criteria for evaluating patient response to therapies in clinical trials are lacking …

Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive disease with inadequate
response to conventional treatment with corticosteroids and/or immunosuppressive agents …